  |
 | Up a level |
Paz-Ares, L. and Chen, Y. and Reinmuth, N. and Hotta, K. and Trukhin, D. and Statsenko, G. and Hochmair, M. J. and Özgüroglu, M. and Ji, J.H. and Garassino, M. C. and Voitko, O. and Poltoratskiy, A. and Musso, E. and Havel, L. and Bondarenko, I. and Losonczy, G. and Conev, N. and Mann, H. and Dalvi, T. B. and Jiang, H. and Goldman, J. W. (2022) Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open, Vol. 7 (no. 2). p. 100408. ISSN 2059-7029 (Online)
Shah, M.A. and Udrea, A.A. and Bondarenko, I. and Mansoor, W. and Sánchez, R.G. and Sarosiek, T. and Bozzarelli, S. and Schenker, M. and Gomez-Martin, C. and Morgan, C. and Özgüroglu, M. and Pikiel, J. and Kalofonos, H.P. and Wojcik, E. and Buchler, T. and Swinson, D. and Cicin, I. and Joseph, M. and Vynnychenko, I. and Luft, A.V. and Enzinger, P.C. and Salek, T. and Papandreou, C. and Tournigand, C. and Maiello, E. and Wei, R. and Ferry, D. and Gao, L. and Oliveira, J.M. and Ajani, J.A. (2022) Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, Vol.14 (iss. 5). p. 1168. ISSN 2072-6694
Li, R.K. and Tokunaga, E. and Adamchuk, H. and Vladimirov, V. and Yanez, E. and Lee, K.S. and Bondarenko, I. and Vana, A. and Hilton, F. and Ishikawa, T. and Tajima, K. and Lipatov, O. (2022) Long‑Term Safety and Efectiveness of PF‑05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2‑Positive Metastatic Breast cancer: Updated Results of a Randomized, Double‑Blind Study. BioDrugs, 36. pp. 55-69. ISSN 1173-8804 (Print) 1179-190X (Online)
Bondarenko, I. and Sezer, A. and Kilickap, S. and Gümüs, M. and Özgüroğlu, M. and Gogishvili, M. and He, X. and Gullo, G. and Rietschel, P. and Quek, R.G. (2022) Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation. Annals of Oncology, Vol.33 (Supp.2). S84-S85. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Rugo, H.S. and Pennella, E.J. and Gopalakrishnan, U. and Hernandez-Bronchud, M. and Herson, J. and Koch, H.F. and Loganathan, S. and Deodhar, S. and Marwah, A. and Manikhas, A. and Bondarenko, I. and Parra, J.D. and Abesamis-Tiambeng, M.L.T. and Akewanlop, C. and Vynnychenko, I. and Sriuranpong, V. and Roy, S. and Yanez Ruiz, E.P. and Barve, A. and Waller, C.F. (2021) Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. The Breast, 58. pp. 18-26. ISSN 0960-9776
Gafanov, R. and Powles, T.B. and Bedke, J. and Stus, V. and Wadde, T.S. and Nosov, D. and Pouliot, F. and Soulières, D. and Melichar, B. and Azevedo, S. and McDermott, R.S. and Vynnychenko, I. and Borchiellini, D. and Markus, M. and Bondarenko, I. and Lin, J. and Burgents, J. and Molife, L. R. and Rini (2021) Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study. Annals of Oncology, 32 (5). p. 694. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Rini, B.I. and Plimack, E.R. and Stus, V. and Gafanov, R. and Hawkins, R. and Nosov, D. and Pouliot, F. and Alekseev, B. and Soulières, D. and Melichar, B. and Vynnychenko, I. and Kryzhanivska, A. and Bondarenko, I. and Azevedo, S.J. and Borchiellini, D. and Szczylik, C. and Markus, M. and McDermott, R.S. and Bedke, J. and Tartas, S. and Chang, Y.-H. and Tamada, S. and Shou, Q. and Perini, R.F. and Chen, M. and Atkins, M.B. and Powles, T. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine = N Engl J Med, 380. pp. 1116-1127. ISSN 0028-4793 (print); 1533-4406 (online)
Sriuranpong, V. and Altundag, O. and Clingan, P. and Rizvi, N. and Aren Frontera, O. and Sezer, A. and Paydas, S. and Shavdia, M. and Bondarenko, I. and Gladkov, O. and Lee, S. and Li, S. and Snodgrass, P. and Rietschel, P. (2018) EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 50%. Annals of Oncology, Vol.29 (Sup.10). mdy487.039. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Zhang, Q. and Xu, B. and Zhang, Q. and Sun, T. and Li, W. and Teng, Y. and Hu, X. and Bondarenko, I. and Adamchuk, H. and Zhang, L. and Trukhin, D. and Wang, S. and Zheng, H. and Tong, Z. and Zhang, X. and Liu, E. and Jiang, W. and Liu, S. and Luk, A. (2018) Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab. Annals of Oncology, Vol.29 (Supp.9). ix16. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Turner, N.C. and Slamon, D.J. and Ro, J. and Bondarenko, I. and Im, S.-A. and Masuda, N. and Colleoni, M. and DeMichele, A. and Loi, S. and Verma, S. and Iwata, H. and Harbeck, N. and Loibl, S. and André, F. and Puyana Theall, K. and Huang, X. and Giorgetti, C. and Huang Bartlett, C. and Cristofanilli, M. (2018) Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine, 379. pp. 1926-1936. ISSN 0028-4793
Cristofanilli, M. and Slamon, D.J. and Ro, J. and Bondarenko, I. and Im, S-A. and Masuda, N. and Colleoni, M. and DeMichele, A. and Loi, S. and Verma, S. and Iwata, H. and Harbeck, N. and Loibl, S. and Andre´, F. and Puyana Theall, K. and Huang, X. and Giorgetti, C. and Huang Bartlett, C. and Turner, N.C. (2018) Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER22) advanced breast cancer (ABC): Analyses from PALOMA-3. Annals of Oncology, Vol.29 (Sapp.8). viii708-viii708. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Lopes, G. and Wu, Y. and Kudaba, I. and Kowalski, D. and Cho, B. and Turna, H. and De Castro, G. and Srimuninnimit, V. and Laktionov, K. and Bondarenko, I. and Kubota, K. and Lubiniecki, G. and Zhang, J. and Kush, D. and Mok, T. (2018) PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%. Journal of Thoracic Oncology, Vol.13 (No. 9S). S152-S154. ISSN 1556-0864
Lopes, G. and Wu, Y. and Kudaba, I. and Kowalski, D. and Cho, B. and Turna, H. and De Castro, G. and Srimuninnimit, V. and Laktionov, K. and Bondarenko, I. and Kubota, K. and Lubiniecki, G. and Zhang, J. and Kush, D. and Mok, T. (2018) Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%. Journal of Thoracic Oncology, Vol.13 (No.9S). S152-S154.
Long, G.V. and Flaherty, K.T. and Stroyakovskiy, D. and Gogas, H. and Levchenko, E. and de Braud, F. and Larkin, J. and Garbe, C. and Jouary, T. and Hauschild, A. and Chiarion-Sileni, V. and Lebbe, C. and Mandala, M. and Millward, M. and Arance, A. and Bondarenko, I. and Haanen, J.B.A.G. and Hansson, J. and Utikal, J. and Ferraresi, V. and Mohr, P. and Probachai, V. and Schadendorf, D. and Nathan, P. and Robert, C. and Ribas, A. and Davies, M.A. and Lane, S.R. and Legos, J.J. and Mookerjee, B. and Grob, J.-J. (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/ K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology, Vol.28 (Iss. 7). pp. 1631-1639. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Hojouj, M.I. and Bondarenko, I. (2016) 111P BMI effect prognostic features of breast cancer treatments. Annals of Oncology, 27 (9suppl). P. mdw-576. 013. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Lordick, F. and Schuler, M. and Al-Batran, S-E. and Zvirbule, Z. and Manikhas, G. and Rusyn, A. and Vinnyk, Y. and Vynnychenko, I. and Fadeeva, N. and Nechaeva, M. and Dudov, A. and Gotovkin, E. and Pecheniy, A. and Bazin, I. and Bondarenko, I. and Melichar, B. and Huber, C. and Sahin, U. and Türeci, Ö. (2016) Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology, 27 (supp_9). mdw582.001. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Heigener, D. and Gottfried, M. and Bennouna, J. and Bondarenko, I. and Douillard, J-Y. and Krzakowski, M. and Mellemgaard, A. and Novello, S. and Orlov, S. and Summers, Y.J. and von Pawel, J. and Hocke, J. and Kaiser, R. and Reck, M. (2016) Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study. Annals of Oncology, 27 (supp_6). 1276P-1276P. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Ellis, M.J. and Bondarenko, I. and Trishkina, E. and Dvorkin, M. and Panasci, L. and Manikhas, A. and Shparyk, Y. and Cardona-Huerta, S. and Cheung, K-L. and Philco-Salas, M.J. and Ruiz-Borrego, M. and Shao, Z. and Noguchi, S. and Grinsted, L.M. and Fazal, M. and Stuart, M. and Robertson, J.F. (2016) FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. Annals of Oncology, Vol.27 (supp6). P.-LBA14_PR. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Schuler, M. and Al-Batran, S.-E. and Zvirbule, Z. and Manikhas, G. and Lordick, F. and Rusyn, A. and Vinnyk, Y. and Vynnychenko, I. and Fadeeva, N. and Nechaeva, M. and Dudov, A. and Gotovkin, E. and Pecheniy, A. and Bazin, I. and Bondarenko, I. and Melichar, B. and Huber, C. and Türeci, Ö. and Sahin, U. (2016) Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology, Vol.27 (supp_6). P.- LBA45. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Spigel, D.R. and Bondarenko, I. and Losonczy, G. and Mezger, J. and Kalofonos, H. and Reck, M. and Palmero, R. and Jang, T. and Natale, R. and Sanborn, R.E. and Lai, J. and Kallinteris, N. and Tang, M. and Shan, J. and Gerber, D. (2016) Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer. Annals of Oncology, Vol.27 (supp_6). P.- LBA45. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Long, G.V. and Stroyakovskiy, D. and Gogas, H. and Levchenko, E. and de Braud, F. and Larkin, J. and Garbe, C. and Jouary, T. and Hauschild, A. and Grob, J.J. and Chiarion Sileni, V. and Lebbe, C. and Mandalà, M. and Millward, M. and Arance, A. and Bondarenko, I. and Haanen, J.B.A.G. and Hansson, J. and Utikal, J. and Ferraresi, V. and Kovalenko, N. and Mohr, P. and Probachai, V. and Schadendorf, D. and Nathan, P. and Robert, C. and Ribas, A. and DeMarini, D.J. and Irani, J.G. and Casey, M. and Ouellet, D. and Martin, A.-M. and Le, N. and Patel, K. and Flaherty, K. (2014) Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. The New England Journal of Medicine = N Engl J Med, 371. pp. 1877-1888. ISSN 0028-4793 (print); 1533-4406 (online)
Rugo, H.S. and Rossi, G. and Rizzi, G. and Borroni, M.E. and Lorusso, V. and Kapthaus, M. and Bondarenko, I. and Sarosiek, T.J. and Aapro, M.S. (2013) NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron. American Association for Cancer Research, 73 (Sup.24).
